Multi-omics analyses reveal ClpP activators disrupt essential mitochondrial pathways in triple-negative breast cancer

ClpP activators ONC201 and related small molecules (TR compounds, Madera Therapeutics), have demonstrated significant anti-cancer potential in vitro and in vivo studies, including clinical trials for refractory solid tumors. Though progress has been made in identifying specific phenotypic outcomes f...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Emily M. J. Fennell, Lucas J. Aponte-Collazo, Wimal Pathmasiri, Blake R. Rushing, Natalie K. Barker, Megan C. Partridge, Yuan-Yuan Li, Cody A. White, Yoshimi E. Greer, Laura E. Herring, Stanley Lipkowitz, Susan C. J. Sumner, Edwin J. Iwanowicz, Lee M. Graves
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Frontiers Media S.A. 2023-03-01
Serie:	Frontiers in Pharmacology
Soggetti:	ClpP activators CLPP mitochondria multi-omics breast cancer
Accesso online:	https://www.frontiersin.org/articles/10.3389/fphar.2023.1136317/full
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!